

PERSONAL INFORMATION

Alessandra Raimondi

Sex female

Date of birth September 27th, 1989 in Legnano (MI) - Italy

Nationality Italian

EDUCATION AND TRAINING

Medical Oncologist

November 2020

Postgraduate Specialization in Medical Oncology by University of Milan at Fondazione IRCCS Istituto Nazionale dei Tumori – Milan, defending a thesis entitled "Nivolumab plus ipilimumab and temozolomide in combination in microsatellite stable, *MGMT* silenced metastatic colorectal cancer: the MAYA study" with score 70/70 cum Laude.

November 2015 – October 2020

Oncologist in training – University of Milan

February 2015

Medical License – University of Milan

July 2014

Graduation by University of Milan defending a thesis entitled "Evaluation of the prognostic role of CD133 in patients with locally advanced Non Small Cell Lung Cancer treated with neoadjuvant chemotherapy followed by surgery: results of a single institution trial" with score 110/110 cum Laude.

December 2013 – July 2014

Training by "Clinical Oncology Department" – Fondazione IRCCS Istituto Nazionale dei Tumori – Milan, Italy

March 2013 – May 2013

Internship by "Adult Mesenchymal Tumours Medical Oncology Unit" – Fondazione IRCCS Istituto Nazionale dei Tumori – Milan, Italy

September 2012 – December 2012

Internship by "Clinical Oncology Department" - A.O.U. San Paolo – Milan, Italy

2008

High school degree at Liceo Scientifico Classico "Galileo Galilei" Legnano (MI) with score full marks cum Laude.

9/11/2020

Alessandra Raimondi

WORK EXPERIENCE

August 2019 – October 2020

Oncologist in training by Gastrointestinal Oncology Unit and ENETS Center of Excellence, Medical Oncology Department – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

February - July 2019

Oncologist in training by Melanoma Unit, Medical Oncology Department – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

October 2018 - January 2019

Oncologist in training by Breast Cancer Unit, Medical Oncology Department – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

April 2018 – September 2018

Oncologist in training by Genito-urinary Unit, Medical Oncology Department – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

November 2017 – March 2018

Oncologist in training by Gastrointestinal Oncology Unit and ENETS Center of Excellence, Medical Oncology Department – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

May 2017 – October 2017

Oncologist in training by "Palliative and Supportive Care Unit" – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

24 – 29 March 2017 Participation at the 16th ESO-ESMO Masterclass in Clinical Oncology

November 2016 – April 2017

Oncologist in training by "Adult Mesenchymal Tumours Medical Oncology Unit" – Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

August 2016 – October 2016

Oncologist in training by "General Medicine Department" – Fondazione IRCCS Policlinico Ca' Granda – Milan

February 2016 – July 2016

Oncologist in training by "Clinical Oncology Department" - Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

November 2015 – January 2016

Oncologist in training by "Immune therapy in Cancers and Innovative Treatments Unit" - Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy, with a training focused on patients enrolled in phase I trials in solid tumors

March 2015 – June 2015

Collaboration in activities of completing Case Report Forms of Clinical Trials by Thoracic Oncology Unit - Fondazione IRCCS Istituto Nazionale Tumori – Milan, Italy

Affiliations Active member of AIOM – Associazione Italiana di Oncologia Medica
Active member of ESMO – European Society of Medical Oncology
Active member of ASCO – American Society of Clinical Oncology
Active member of ITANET

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
Self Assessment					
French	A2	A2	A2	A2	A2
Self Assessment					

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
Common European Framework of Reference for Languages

Digital competence	SELF-ASSESSMENT				
	Information processing	Communication	Content creation	Safety	Problem solving
	Basic user	Basic user	Basic user	Basic user	BASIC USER

Levels: Basic user - Independent user - Proficient user
Digital competences - Self-assessment grid

Driving licence Driving licence category: B

Additional skills January 2016 GCP Training completed, Good Clinical Practice (Investigator Version) version #1.0

List of publications

Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.

Ratta R, Verzoni E, Mennitto A, Pantano F, Martinetti A, **Raimondi A**, Sepe P, Sottotetti E, Mennitto R, Morelli D, Santini D, de Braud FG, Procopio G. Tumori. 2020 Nov 5:300891620969817. doi: 10.1177/0300891620969817. Online ahead of print. PMID: 33153416

Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial.

Pietrantonio F, Fucà G, Manca P, Pagani F, **Raimondi A**, Prisciandaro M, Randon G, Corti F, de Braud F, Cremolini C, Miceli R. Tumori. 2020 Oct 6:300891620960808. doi: 10.1177/0300891620960808. Online ahead of print. PMID: 33021466

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.

Raimondi A, Sepe P, Zattarin E, Mennitto A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F, Procopio G. Front Oncol. 2020 Aug 12;10:1644. doi: 10.3389/fonc.2020.01644. eCollection 2020.

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors.

Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, **Raimondi A**, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. J Clin Med. 2020 Aug 1;9(8):2468. doi: 10.3390/jcm9082468.

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.

Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, Greco FG, Frezza AM, Casali PG, Stacchiotti S. ESMO Open. 2020 Jul;5(4):e000663. doi: 10.1136/esmoopen-2019-000663. PMID: 32661185

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.

Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F. Eur J Cancer. 2020 Jul 2;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Online ahead of print. PMID: 32623288

Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.

Di Bartolomeo M, **Raimondi A**, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamberi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA, Pietrantonio F. Tumori. 2020 Jun 11:300891620930803. doi: 10.1177/0300891620930803. Online ahead of print. PMID: 32522106

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan.

Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, **Raimondi A**, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Clin Colorectal Cancer. 2020 May 23:S1533-0028(20)30077-3. doi: 10.1016/j.clcc.2020.05.004. Online ahead of print. PMID: 32513593

Prospective Translational Study Investigating Molecular Predictors of Resistance to First-Line Pazopanib in Metastatic renal Cell Carcinoma (PIPELINE Study).

Sepe P, Martinetti A, Mennitto A, Verzoni E, Claps M, **Raimondi A**, Sottotetti E, Grassi P, Guadalupi V, Stellato M, Zattarin E, Di Maio M, Procopio G. Am J Clin Oncol. 2020 May 27. doi: 10.1097/COC.0000000000000719. Online ahead of print. PMID: 32467528

Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori.

Raimondi A, Sepe P, Claps M, Maccauro M, Aliberti G, Pagani F, Apollonio G, Randon G, Peverelli G, Seregini E, Verzoni E, Procopio G. Tumori. 2020 Mar 2:300891620905646. doi: 10.1177/0300891620905646. Online ahead of print. PMID: 32116138

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

Pietrantonio F, Loupakis F, Randon G, **Raimondi A**, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. *Oncologist*. 2020 May 5. doi: 10.1634/theoncologist.2020-0014. Online ahead of print. PMID: 32369650

Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.

Corallo S, Fucà G, Morano F, Salati M, Spallanzani A, Gloghini A, Volpi CC, Trupia DV, Lobefaro R, Guarini V, Milione M, Cattaneo L, Antista M, Prisciandaro M, **Raimondi A**, Sposito C, Mazzaferro V, de Braud F, Pietrantonio F, Di Bartolomeo M. *Oncologist*. 2020 Apr 9. doi: 10.1634/theoncologist.2020-0037. Online ahead of print. PMID: 32272500

Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.

Di Bartolomeo M, Morano F, **Raimondi A**, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. *Oncologist*. 2020 Mar;25(3):e460-e468. doi: 10.1634/theoncologist.2019-0471. Epub 2019 Nov 25. PMID: 32162808

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Pietrantonio F, Miceli R, **Raimondi A**, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. *J Clin Oncol*. 2019 Dec 10;37(35):3392-3400. doi: 10.1200/JCO.19.01124. Epub 2019 Sep 12. PMID: 31513484

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.

Pietrantonio F, Lobefaro R, Antista M, Lonardi S, **Raimondi A**, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F. *Clin Cancer Res*. 2020 Mar 1;26(5):1017-1024. doi: 10.1158/1078-0432.CCR-19-3024. Epub 2019 Nov 18. PMID: 31740551

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, **Raimondi A**, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. *J Clin Oncol*. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20. PMID: 31539295

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.

Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, **Raimondi A**, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, Verzoni E. *Eur Urol Oncol*. 2019 Nov;2(6):699-707. doi: 10.1016/j.euo.2019.08.011. Epub 2019 Sep 19. PMID: 31542243

The Landscape of Actionable Gene Fusions in Colorectal Cancer.

Pagani F, Randon G, Guarini V, **Raimondi A**, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. *Int J Mol Sci*. 2019 Oct 25;20(21):5319. doi: 10.3390/ijms20215319. PMID: 31731495

Atypical RAS Mutations in Metastatic Colorectal Cancer

Pietrantonio F, Yaeger R, Schrock AB, Randon G, Romero-Cordoba S, Rossini D, Fucà G, Ross JS, Kotani D, Madison R, Kim ST, Salvatore L, **Raimondi A**, Pagani F, Borelli B, Perrone F, Di Bartolomeo M, Miller VA, Ali SM, Lee J, Yoshino T, de Bradu F, Falcone A, Hechtman JF, Cremolin C. DOI: 10.1200/PO.19.00136 *JCO Precision Oncology* - published online September 17, 2019

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
 Prinzi N, **Raimondi A**, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, Russo GL, Giacomelli L, Mazzaferro V, Bartolomeo MD, Seregni E, Braud F, Pusceddu S. *Future Oncol.* 2019 Sep;15(26):3015-3024. doi: 10.2217/fon-2019-0138. Epub 2019 Aug 19. PMID: 31424273

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
Raimondi A, Sepe P, Claps M, Verzoni E, Procopio G. *Expert Opin Biol Ther.* 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6. PMID: 31369337

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
 Peverelli G, **Raimondi A**, Ratta R, Verzoni E, Bregni M, Cortesi E, Carteni G, Fornarini G, Facchini G, Buti S, Galli L, Tucci M, Prisciandaro M, Procopio G. *Clin Genitourin Cancer.* 2019 Aug;17(4):291-298. doi: 10.1016/j.clgc.2019.05.002. Epub 2019 May 13. PMID: 31178240

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G. *Int J Mol Sci.* 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263. PMID: 31480348

The role of metastasectomy in advanced renal cell carcinoma.
 Apollonio G, **Raimondi A**, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G. *Expert Rev Anticancer Ther.* 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8. PMID: 31159619

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial.
 Miceli R, An J, Di Bartolomeo M, Morano F, Kim ST, Park SH, Choi MG, Lee JH, **Raimondi A**, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, Pietrantonio F, Lee J. *Oncology.* 2019;97(1):38-43. doi: 10.1159/000499628. Epub 2019 May 2. PMID: 31048579

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
 Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, **Raimondi A**, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smirardo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. *JAMA Oncol.* 2019 Jul 3;5(9):1268-75. doi: 10.1001/jamaoncol.2019.1467. Online ahead of print. PMID: 31268481

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
 Verzoni E, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, **Raimondi A**, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. *J Immunother Cancer.* 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. PMID: 30944023

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. *Clin Colorectal Cancer.* 2019 Jun;18(2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1. PMID: 31023524

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.
 Randon G, Fucà G, Rossini D, **Raimondi A**, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. *Sci Rep.* 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3. PMID: 30814645

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
 Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, **Raimondi A**, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. *Eur J Cancer.* 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19. PMID: 30579113

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, **Raimondi A**, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24. PMID: 30558859

Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies.

Raimondi A, Nichetti F, Peverelli G, Di Bartolomeo M, De Braud F, Pietrantonio F. Pharmacogenomics. 2018 Aug 1;19(13):1047-1068. doi: 10.2217/pgs-2018-0077. Epub 2018 Jul 25. PMID: 30041572

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Pusceddu S, Prinzi N, **Raimondi A**, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Tumori. 2019 Apr;105(2):113-120. doi: 10.1177/0300891618765362. Epub 2018 Apr 6. PMID: 29714658

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, **Raimondi A**, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197. PMID: 29860358

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

Corti F, Nichetti F, **Raimondi A**, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S. Cancer Treat Rev. 2019 Jan;72:45-55. doi: 10.1016/j.ctrv.2018.11.001. Epub 2018 Nov 10. PMID: 30476750

Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.

Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S. Anticancer Drugs. 2018 Jul;29(6):589-595. doi: 10.1097/CAD.0000000000000634. PMID: 29668485

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Nichetti F, Marra A, Corti F, Guidi A, **Raimondi A**, Prinzi N, de Braud F, Pusceddu S. Target Oncol. 2018 Jun;13(3):333-351. doi: 10.1007/s11523-018-0567-0. PMID: 29656320

Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study.

Caraceni A, Speranza R, Spoldi E, Ambroset CS, Canestrari S, Marinari M, Marzi AM, Orsi L, Piva L, Rocchi M, Valenti D, Zeppetella G, Zucco F, **Raimondi A**, Matos LV, Brunelli C; Italian Society of Palliative Care Study Group on Palliative Sedation in Adult Cancer Patients. J Pain Symptom Manage. 2018 Jul;56(1):33-43. doi: 10.1016/j.jpainsymman.2018.03.008. Epub 2018 Mar 13. PMID: 29548893

Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.

Vernieri C, Nichetti F, **Raimondi A**, Pusceddu S, Platania M, Berrino F, de Braud F. Crit Rev Oncol Hematol. 2018 Mar;123:57-73. doi: 10.1016/j.critrevonc.2018.01.002. Epub 2018 Feb 2. PMID: 29482780

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor.

Provenzano S, **Raimondi A**, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, Fiore M, Greco FG, Casali PG. Clin Sarcoma Res. 2017 Dec 28;7:20. doi: 10.1186/s13569-017-0086-2. eCollection 2017. PMID: 29299229

Abstracts and Posters

Ongaro E, Rossini D., Pietrantonio F., Morano F., De Braud F., Mazzaferro V., Corti F., Randon G., Raimondi A., Battaglia L., Morelli L., Urbani L., Masi G., Moretto R., Antoniotti C., Marmorino F., Borelli B., Zucchelli G., Boccaccino A., Cremolini C. and Falcone A. Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liverlimited metastatic colorectal cancer (mCRC) Acta Congr. AIOM 2018 XX National Congress of Oncology – B20

Raimondi A., Corallo S., Niger M., Antista M., Randon G., Morano F., Cremolini C., Di Bartolomeo M., De Braud F. and Pietrantonio F. Potential prognostic markers in unresectable or relapsed Pseudomyxoma Peritonei (PMP) treated with metronomic capecitabine plus cyclophosphamide regimen. Acta Congr. AIOM 2018 XX National Congress of Oncology – C14

Rivoltini L., Ferro S., Procopio G., Cova A., Ratta R., Raimondi A., Sepe P., Squarcina P., Lalli L., Huber V., Rinchai D., Bedognetti D. and Verzoni E. Potent Natural Killer (NK) and myeloid blood cell remodeling by Cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients. Acta Congr. AIOM 2018 XX National Congress of Oncology – G01

Pietrantonio F., Morano F., Raimondi A., Corallo S., Cremolini C., Lonardi S., Rimassa L., Sartore-Bianchi A., Murialdo R., Zaniboni A., Adamo V., Tomaselto G., Tampellini M., Fanchini L., Schirripa M., Clavarezza M., Petrelli F., Longarini R., Di Bartolomeo M., De Braud F. Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or single-agent Pan: translational analyses of the VALENTINO study. Acta Congr. AIOM 2018 XX National Congress of Oncology – B*LBA3037

Raimondi A, Prinzi N, Corti F, Nichetti F, Torchio M, Buzzoni R, De Braud F, Pusceddu S A case report of long-lasting complete response to anti-pd1-1 treatment in merkel cell carcinoma (mcc): what is the optimal duration of immunotherapy? Acta Congr. ITANET2018

Raimondi A, Prinzi N, Corti F, Buzzoni R, De Braud F, Pusceddu S Indicazione e timing della peptide receptor radionuclide therapy (PRRT) in un caso di tumore neuroendocrino (NET) del pancreas avanzato con sindrome da carcinoide severa - Abstract NEN 2018 Firenze

Prinzi N, Raimondi A, Seregni E, Maccauro M, Capozza A, Follacchio GA, Lo Russo G, Buzzoni R, De Braud F, Pusceddu S. Peptide receptor radionuclide therapy (PRRT) in combinazione con analoghi della somatostatina (SSA) nei tumori neuroendocrini ben differenziati del midgut: quale sequenza terapeutica alla progressione con SSA? - Abstract NEN 2018 Firenze

Femia D, Prinzi N, Pusceddu S, Concas L, Lo Russo G, Vernieri C, Milione M, Dinoi G, Raimondi A, Prisciandaro M, de Braud F, Buzzoni R. Complete response to avelumab in Merkel Cell Carcinoma, and potential correlation with toxicity: a case report Acta Congr. AIOM 2016 XVIII National Congress of Oncology – S42

Agustoni F, Fucà G, Corrao G, Vernieri C, Cavaliere S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Lo Russo G, Signorelli D, Proto C, Vitali M, Imbimbo M, Zilembo N, Garassino MC, Procopio G, de Braud F, Morelli D, Platania M. Impact of Hyponatremia in a Tertiary Cancer Center: A one-year-Survey at National Cancer Institute of Milan Acta Congr. AIOM 2016 XVIII National Congress of Oncology – S19

Cavaliere S, Raimondi A, Morelli D, Martinetti A, de Braud F, Agustoni F, Dotti K, Galli G, Vernieri C, Fucà G, Peverelli G, Prisciandaro M, Nichetti F, Indelicato P, Lo Russo G, Prinzi N, Garassino M, Platania M. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. Acta-Congr. AIOM 2016 XVIII National Congress of Oncology – A34

LoRusso G, Macerelli M, Proto C, Vitali M, Signorelli D, Gallucci R, Platania M, Agustoni F, Zilembo N, Ganzinelli M, Raimondi A, Trama A, de Braud F, Garassino MC. Absence of standard in the management of Thymic Epithelial Tumors Acta Congr. AIOM 2015 XVII National Congress of Oncology – H23

Raimondi A, Corallo S, Niger M, Antista M, Randon G., Morano F, Cremolini C, Di Bartolomeo M, De Braud F, Pietrantonio F Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed Pseudomyxoma Peritonei – 581P ESMO 2018 Poster - Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018

Pietrantonio F, Raimondi A, Choi YY, Kang W, Langley R, Kim YW, Kim KM, Nankivell MG, Perrone F, Kook MC, An JY, Grabsch H, Morano F, Cheong JH, Noh SH, Lee J, Cunningham D, Di Bartolomeo M, Fucà G, Smyth EC MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs). Acta Congr. ASCO Gastrointestinal Cancers Symposium 2019 - Abstract 66